Oncotarget Moves Forward with Their Accomplishments with Cancer

Beginning at 2010, Oncotarget had began its origins as a traditional multidisciplinary journal that had an initial focus on oncology, the science of preventing diseases. Oncotarget was particularly focused on using the study of oncology as a method to eliminate cancer.

Oncotarget is still focus on that particular goal of the elimination of cancer but its methods have since been updated.

One method that has been updated to fit within the current times is the fact that Oncotarget had focused around its core values around democratization. In other words, keeping the journal itself open and free to be used.

The demonstration of democratization from Oncotarget is through the implementation of Creative Commons Attribution 3.0 License that the journal actively supports.

Those who are unaware about Creative Commons Attribution 3.0 License, it allows researchers to share their research papers through the scientific community allowing for more tests and experiments to finish more expediently.

The democratization isn’t just regulated to just the scientists and researchers of that field. In fact, it’s meant for everyone to openly see the published reports.

Oncology originally was the only topic that Oncotarget had continued to focus on but it has also incorporated other subjects such immunology, chromosomes, and autophagy.

The result of the democratization and the license that enable for the research papers to be easily shared, it’s no wonder that a lot of research papers have been shared easily and freely. Listen to an audio podcast of Oncotarget on Itunes.

Accomplishments with Oncotarget’s Media Platform

Oncotarget has also been accomplished its stated objectives when it comes to its media landscape goals altogether.

One of Oncotarget’s earlier stated goals was that they were going to create a twice-weekly publication by transforming their once-weekly publication schedule into a twice-weekly publication that releases new issues on both Tuesday and Friday.

The outcome would be a two-fold solution.

The first solution that resulted from is that readers would be able to stay current with the breakthroughs that were occurring in Oncotarget. The second solution is that the media consumers would be able to avoid the hiatuses and gaps in the production schedule.

With that forward-moving approach with transforming the weekly publication into a twice-weekly publication, Oncotarget had also set its sights on the creation of their podcast.

The podcast’s objective would be to serve the listeners in hearing about the breakthroughs.

The podcast episodes are exceptionally brief. Therefore, the collection of the information from the episodes were very digestible.

Also, having it in the form of a podcast allows people to consume the information in more accessible manner. Follow Oncotarget journal on Twitter.

The podcast is currently available on Stitcher, Player. FM, Soundcloud, and iTunes.

Oncotarget’s Other Worthy Achievements

Oncotarget has also involved with other accomplishments besides the aforementioned.

One shining achievement that Oncotarget has had thus far is maintaining their impact factor score of 5.168. This can because of Oncotarget’s open and free nature that the journal itself embodies.

This is also shows that Oncotarget is gaining influence and is making an impact.

Another accomplishment that is notable is that Oncotarget researchers have been able to identify proven new therapeutic strategies to treat thyroid cancer.

Oncotarget is currently indexed by most scientific databases such as BIOSIS Previews, Journal Citation Reports/Science Edition, Embase, and Biological Abstracts.

Oncotarget’s noteworthy accomplishments have been notable and recognized.

Progress with Oncology in an Open and Free Way

With the research being published in Oncotarget at a faster pace, the core value of democratization upholds is showing its effect.

Read more: http://www.scimagojr.com/journalsearch.php?q=19900191708&tip=sid

Leave a Reply

Your email address will not be published. Required fields are marked *